July 17, 2025
MOMA Therapeutics
MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor
July 17, 2025
Seaport Therapeutics
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 14, 2025
Marea Therapeutics
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
July 01, 2025
Marea Therapeutics
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
June 27, 2025
Tango Therapeutics
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer